Ghozy Sherief, Orscelik Atakan, Tolba Hatem, Abdelghaffar Mariam, Kobeissi Hassan, Ghaith Hazem S, Abbas Alzhraa S, Kadirvel Ramanathan, Brinjikji Waleed, Kallmes David F
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA.
Interv Neuroradiol. 2024 Sep 30:15910199241285071. doi: 10.1177/15910199241285071.
Cerebral sinus venous thrombosis (CSVT) has traditionally been treated medically with systemic anticoagulation. Recent advances in endovascular therapy (EVT) may represent an alternative treatment to medical therapy for CSVT. We conducted a systematic review and meta-analysis to evaluate the use of EVT for CSVT.
We conducted a systematic literature review using PubMed, Embase, Scopus, and Web of Science. We included studies that reported outcomes following EVT for CSVT. The primary outcome of interest was rate of modified Rankin Scale (mRS) 0-2. Secondary outcomes of interest were rates of complete, partial, and failed recanalization, mortality, and new or expansion of hematoma. We calculated pooled rates (%) and their corresponding 95% confidence intervals (CIs).
Thirty-eight studies with 682 patients were included. Rate of mRS 0-2 was 82.6% (95% CI, 75.3%-88.0%). Rate of complete recanalization was 60.9% (95% CI, 49.1%-71.5%), rate of partial recanalization was 34.2% (95% CI, 24.1%-45.9%), and rate of failed recanalization was 5.4% (95% CI, 3.1%-9.2%). Rate of mortality was 6.7% (95% CI, 4.1%-10.8%), and rate of new hematoma or expansion of hematoma was 5.1% (2.9%-8.8%).
In this systematic review and meta-analysis, EVT for CSVT was associated with favorable rates of mRS 0-2 and recanalization. Furthermore, EVT was associated with a promising safety profile. Future prospective, comparative studies are warranted to assess EVT for CSVT.
传统上,脑静脉窦血栓形成(CSVT)采用全身抗凝药物治疗。血管内治疗(EVT)的最新进展可能代表了CSVT药物治疗的替代方案。我们进行了一项系统评价和荟萃分析,以评估EVT在CSVT治疗中的应用。
我们使用PubMed、Embase、Scopus和Web of Science进行了系统的文献综述。我们纳入了报告CSVT接受EVT治疗后结果的研究。感兴趣的主要结局是改良Rankin量表(mRS)评分为0 - 2的比例。感兴趣的次要结局是完全再通、部分再通和再通失败的比例、死亡率以及血肿新出现或扩大的比例。我们计算了合并比例(%)及其相应的95%置信区间(CI)。
纳入了38项研究,共682例患者。mRS评分为0 - 2的比例为82.6%(95%CI,75.3% - 88.0%)。完全再通的比例为60.9%(95%CI,49.1% - 71.5%),部分再通的比例为34.2%(95%CI,24.1% - 45.9%),再通失败的比例为5.4%(95%CI,3.1% - 9.2%)。死亡率为6.7%(95%CI,4.1% - 10.8%),血肿新出现或扩大的比例为5.1%(2.9% - 8.8%)。
在这项系统评价和荟萃分析中,CSVT的EVT治疗与良好的mRS 0 - 2评分和再通率相关。此外,EVT具有良好的安全性。未来有必要进行前瞻性、比较性研究,以评估CSVT的EVT治疗效果。